Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD
FLT3-ITD mutations are common druggable alterations in patients with acute myeloid leukemia (AML) and associated with poor prognosis. Beside typical ITD mutations, point mutations and deletions in the juxtamembrane domain (JMD) have been observed. However, due to the low frequency of these alteratio...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
21 March 2022
|
| In: |
Frontiers in oncology
Year: 2022, Jahrgang: 12, Pages: 1-6 |
| ISSN: | 2234-943X |
| DOI: | 10.3389/fonc.2022.862991 |
| Online-Zugang: | Resolving-System, lizenzpflichtig, Volltext: https://doi.org/10.3389/fonc.2022.862991 Verlag, lizenzpflichtig, Volltext: https://www.frontiersin.org/article/10.3389/fonc.2022.862991 
|
| Verfasserangaben: | Sebastian Stasik, Michael Kramer, Sven Zukunft, Christoph Röllig, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Carsten Müller-Tidow, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan Krause, Tim Sauer, Mathias Hänel, Andreas Neubauer, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke and Christian Thiede on behalf of the Study Alliance Leukemia (SAL) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1802476342 | ||
| 003 | DE-627 | ||
| 005 | 20230525084106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220518s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fonc.2022.862991 |2 doi | |
| 035 | |a (DE-627)1802476342 | ||
| 035 | |a (DE-599)KXP1802476342 | ||
| 035 | |a (OCoLC)1341460215 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Stasik, Sebastian |d 1984- |e VerfasserIn |0 (DE-588)1074896149 |0 (DE-627)832659827 |0 (DE-576)443102309 |4 aut | |
| 245 | 1 | 0 | |a Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD |c Sebastian Stasik, Michael Kramer, Sven Zukunft, Christoph Röllig, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Carsten Müller-Tidow, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan Krause, Tim Sauer, Mathias Hänel, Andreas Neubauer, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke and Christian Thiede on behalf of the Study Alliance Leukemia (SAL) |
| 264 | 1 | |c 21 March 2022 | |
| 300 | |a 6 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.05.2022 | ||
| 520 | |a FLT3-ITD mutations are common druggable alterations in patients with acute myeloid leukemia (AML) and associated with poor prognosis. Beside typical ITD mutations, point mutations and deletions in the juxtamembrane domain (JMD) have been observed. However, due to the low frequency of these alterations, there is only limited information on molecular and clinical associations. To evaluate the prognostic impact of non-ITD mutations in the FLT3 JMD region, we analyzed a large cohort of 1,539 adult AML patients treated in different protocols of the Study Alliance Leukemia, using next-generation sequencing. Non-ITD point mutations and deletions within the FLT3 JMD were identified with a prevalence of ~1.23% (n = 19). Both FLT3-ITD and non-ITD mutations were associated with a higher rate of NPM1 (42%-61%; p < 0.001) and DNMT3A mutations (37%-43%; p < 0.001), as well as an increased percentage of peripheral blood (54%-65%) and bone marrow blast cells (74%; p < 0.001), compared to FLT3-wild-type patients. Most significantly, AML patients with FLT3 non-ITD mutations had a higher rate of concomitant KMT2A-PTD mutations (37.5%; p < 0.001) as compared to FLT3-ITD (7%) or FLT3-wild-type cases (4.5%). In a multivariable analysis, FLT3 non-ITD mutations were not an independent prognostic factor. However, patients with dual FLT3 non-ITD and KMT2A-PTD mutations showed a trend for inferior outcome, which points at a functional interaction in this subset of AML. | ||
| 700 | 1 | |a Kramer, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zukunft, Sven |e VerfasserIn |4 aut | |
| 700 | 1 | |a Röllig, Christoph |e VerfasserIn |4 aut | |
| 700 | 1 | |a Baldus, Claudia D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e VerfasserIn |4 aut | |
| 700 | 1 | |a Serve, Hubert |e VerfasserIn |0 (DE-588)1169095399 |0 (DE-627)1032734256 |0 (DE-576)511922388 |4 aut | |
| 700 | 1 | |a Müller-Tidow, Carsten |d 1968- |e VerfasserIn |0 (DE-588)1015101798 |0 (DE-627)705330230 |0 (DE-576)351197893 |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kaufmann, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krause, Stefan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sauer, Tim |d 1981- |e VerfasserIn |0 (DE-588)138282013 |0 (DE-627)601099516 |0 (DE-576)307058166 |4 aut | |
| 700 | 1 | |a Hänel, Mathias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Neubauer, Andreas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ehninger, Gerhard |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bornhäuser, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schetelig, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Middeke, Jan M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thiede, Christian |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in oncology |d Lausanne : Frontiers Media, 2011 |g 12(2022), Artikel-ID 862991, Seite 1-6 |h Online-Ressource |w (DE-627)684965518 |w (DE-600)2649216-7 |w (DE-576)35841184X |x 2234-943X |7 nnas |a Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g elocationid:862991 |g pages:1-6 |g extent:6 |a Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD |
| 856 | 4 | 0 | |u https://doi.org/10.3389/fonc.2022.862991 |x Resolving-System |x Verlag |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.frontiersin.org/article/10.3389/fonc.2022.862991 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220518 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 138282013 |a Sauer, Tim |m 138282013:Sauer, Tim |d 910000 |d 910100 |e 910000PS138282013 |e 910100PS138282013 |k 0/910000/ |k 1/910000/910100/ |p 12 | ||
| 998 | |g 1015101798 |a Müller-Tidow, Carsten |m 1015101798:Müller-Tidow, Carsten |d 910000 |d 910100 |e 910000PM1015101798 |e 910100PM1015101798 |k 0/910000/ |k 1/910000/910100/ |p 8 | ||
| 999 | |a KXP-PPN1802476342 |e 4135875947 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"doi":["10.3389/fonc.2022.862991"],"eki":["1802476342"]},"physDesc":[{"extent":"6 S."}],"title":[{"title":"Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD","title_sort":"Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTD"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2022","dateIssuedDisp":"21 March 2022"}],"relHost":[{"recId":"684965518","origin":[{"dateIssuedKey":"2011","publisherPlace":"Lausanne","publisher":"Frontiers Media","dateIssuedDisp":"2011-"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["684965518"],"issn":["2234-943X"],"zdb":["2649216-7"]},"title":[{"title_sort":"Frontiers in oncology","title":"Frontiers in oncology"}],"note":["Gesehen am 07.11.13"],"pubHistory":["2011 -"],"part":{"pages":"1-6","extent":"6","text":"12(2022), Artikel-ID 862991, Seite 1-6","year":"2022","volume":"12"},"language":["eng"],"disp":"Point mutations in the FLT3-ITD region are rare but recurrent alterations in adult AML and associated with concomitant KMT2A-PTDFrontiers in oncology","type":{"bibl":"periodical","media":"Online-Ressource"}}],"language":["eng"],"name":{"displayForm":["Sebastian Stasik, Michael Kramer, Sven Zukunft, Christoph Röllig, Claudia D. Baldus, Uwe Platzbecker, Hubert Serve, Carsten Müller-Tidow, Kerstin Schäfer-Eckart, Martin Kaufmann, Stefan Krause, Tim Sauer, Mathias Hänel, Andreas Neubauer, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig, Jan M. Middeke and Christian Thiede on behalf of the Study Alliance Leukemia (SAL)"]},"note":["Gesehen am 18.05.2022"],"person":[{"given":"Sebastian","display":"Stasik, Sebastian","family":"Stasik","role":"aut"},{"given":"Michael","display":"Kramer, Michael","role":"aut","family":"Kramer"},{"display":"Zukunft, Sven","given":"Sven","family":"Zukunft","role":"aut"},{"given":"Christoph","display":"Röllig, Christoph","role":"aut","family":"Röllig"},{"family":"Baldus","role":"aut","display":"Baldus, Claudia D.","given":"Claudia D."},{"role":"aut","family":"Platzbecker","given":"Uwe","display":"Platzbecker, Uwe"},{"given":"Hubert","display":"Serve, Hubert","role":"aut","family":"Serve"},{"family":"Müller-Tidow","role":"aut","display":"Müller-Tidow, Carsten","given":"Carsten"},{"family":"Schäfer-Eckart","role":"aut","given":"Kerstin","display":"Schäfer-Eckart, Kerstin"},{"given":"Martin","display":"Kaufmann, Martin","role":"aut","family":"Kaufmann"},{"family":"Krause","role":"aut","given":"Stefan","display":"Krause, Stefan"},{"display":"Sauer, Tim","given":"Tim","role":"aut","family":"Sauer"},{"role":"aut","family":"Hänel","display":"Hänel, Mathias","given":"Mathias"},{"display":"Neubauer, Andreas","given":"Andreas","family":"Neubauer","role":"aut"},{"family":"Ehninger","role":"aut","given":"Gerhard","display":"Ehninger, Gerhard"},{"role":"aut","family":"Bornhäuser","display":"Bornhäuser, Martin","given":"Martin"},{"given":"Johannes","display":"Schetelig, Johannes","family":"Schetelig","role":"aut"},{"given":"Jan M.","display":"Middeke, Jan M.","role":"aut","family":"Middeke"},{"given":"Christian","display":"Thiede, Christian","family":"Thiede","role":"aut"}],"recId":"1802476342"} | ||
| SRT | |a STASIKSEBAPOINTMUTAT2120 | ||